ADXN
ADXN clinical trials: Addex Therapeutics Ltd.
Every trial on ClinicalTrials.gov where Addex Therapeutics Ltd. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 7
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ADXN on the catalyst calendar · ADXN registry changes
- Primary completion Oct 27, 2022ActualPhase 2NCT05027997Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With BlepharospasmAddex Pharma S.A. · BlepharospasmCompletedADXNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2022ActualPhase 2/Phase 3NCT05116813Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based TherapyAddex Pharma S.A. · Parkinson DiseaseTerminatedADXNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2022ActualPhase 2/Phase 3NCT04857359Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based TherapyAddex Pharma S.A. · Parkinson DiseaseTerminatedADXNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2012ActualPhase 2NCT01336088ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's DiseaseAddex Pharma S.A. · Parkinson's DiseaseCompletedADXNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2009ActualPhase 2NCT00810485ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)Addex Pharma S.A. · Gastroesophageal RefluxCompletedADXNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2010Sponsor estimatePhase 2NCT00820105ADX10059 Migraine Prevention StudyAddex Pharma S.A. · MigraineTerminatedADXNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2009ActualPhase 2NCT00820079ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)Addex Pharma S.A. · Gastroesophageal RefluxCompletedADXNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2017ActualPhase 1NCT02447640PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) AdministrationJohns Hopkins University · HealthyCompletedADXNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner